Search
MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.
Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from MSK.
Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.
Dr. Offodile will serve as MSK’s “futurist,” leading strategy efforts and care transformation initiatives at MSK by continuing to develop the core infrastructure, management systems, and processes for enterprise strategy and business development.
Pexidartinib is the first drug approved specifically to treat tenosynovial giant cell tumor.
All radiotherapy treatments for prostate cancer should be accompanied by image-guidance of the prostate position to rule out significant setup errors in fractional delivery.
Memorial Sloan Kettering's Boards of Overseers and Managers have announced the creation of the Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chairs and have named the first two incumbents: Sloan Kettering Institute's Grégoire Altan-Bonnet and Songhai Shi.
James Rothman, who receives this year’s Nobel Prize in Physiology or Medicine together with Randy Schekman and Thomas Südhof, conducted more than a decade of his seminal research at Memorial Sloan Kettering.
Meet Mary Wu, a patient financial services specialist at Memorial Sloan Kettering Westchester.
MSK researchers have found that a genetic state in tumors called whole-genome doubling is connected with worse outcomes for people with cancer.